Ask Onix
A mother's fight as Australia races to eradicate cervical cancer
Twelve years after her terminal diagnosis, Chrissy Walters watches her daughter receive the HPV vaccine that may spare future generations the same fate. Australia stands on the brink of becoming the first country to eliminate cervical cancer, a milestone Walters calls bittersweet.
A decade of survival amid terminal diagnosis
Walters, now 51, was diagnosed with advanced cervical cancer in 2014 after a severe hemorrhage at her Toowoomba home. The mother of one recalls telling her husband, Neil, the news must be a mistake. Despite aggressive treatments-radiation, chemotherapy, and surgeries-the cancer spread. Doctors now classify her condition as terminal.
"I'd never wish this on my worst enemy," Walters says. Her 12-year-old daughter has grown up with the disease as a constant presence, with the family discussing death openly since the child was three.
Australia's path to elimination
In 2006, Australian scientists at the University of Queensland developed Gardasil, the first HPV vaccine. A year later, Australia launched the world's first national vaccination program, targeting girls aged 12-13. The initiative expanded to include boys in 2013, as males can transmit the virus.
HPV, a common sexually transmitted infection, causes nearly all cervical cancers. While most cases resolve without symptoms, high-risk strains can lead to cancer, the fourth most common in women globally. Australia's program, combined with a 2017 shift to more sensitive HPV-based screening every five years, has slashed incidence and mortality rates by half since 1982.
"Public health innovations in Australia set a global example,"
Professor Karen Canfell, epidemiologist
Progress and persistent gaps
Australia's current rate of 6.3 new cases per 100,000 women puts it on track to meet the World Health Organization's (WHO) elimination threshold of fewer than four cases per 100,000 by 2035-possibly sooner. In 2021, no cases were detected in women under 25 for the first time.
Yet challenges remain. Vaccination rates among Aboriginal and Torres Strait Islander communities lag due to healthcare barriers, with cervical cancer rates twice as high and mortality three times greater than the national average. Researchers warn these groups may not reach elimination until 2047.
"Later-stage diagnoses are more common among Indigenous women," says Dr. Natalie Strobel, an epidemiologist. She cites vaccine hesitancy post-COVID, rising medical costs, and school absences as hurdles, noting that missed vaccines often go unaddressed.
Global race and economic barriers
Australia's success has inspired neighbors like Vanuatu and Papua New Guinea, but low- and middle-income countries struggle with funding. Canfell's team argues elimination saves long-term healthcare costs, boosting workforce productivity and economic stability.
Global aid cuts, including the U.S. ending support for Gavi (a vaccine alliance for developing nations) in 2025, threaten progress. "We're fortunate to have universal healthcare," Canfell says, contrasting Australia's system with those lacking resources.
Sweden and Rwanda aim to eliminate cervical cancer by 2027, while the UK targets 2040. Both face declining vaccination and screening rates, underscoring the difficulty of sustaining momentum.
A legacy of hope and hardship
For Walters, managing cervical cancer feels like a "full-time job with no pay." Despite Australia's Medicare subsidies, she describes financial strain, endless appointments, and debilitating side effects from treatments she likens to "being nuked like Chernobyl."
Yet she finds solace in the progress. "It's heartening to think my daughter's generation might never face this," she says. Canfell echoes the sentiment, calling cervical cancer elimination a "global first" for cancer control-a testament to collaboration between scientists, policymakers, and communities.
"This is the first time we've said we'll eliminate a cancer. That's revolutionary."
Professor Karen Canfell
